Juncture Wealth Strategies »

Catalyst Pharmaceutical Partners shares owned by Juncture Wealth Strategies

Quarter-by-quarter ownership of Catalyst Pharmaceutical Partners (CPRX) shares owned by Juncture Wealth Strategies from 13F filings

Historical chart of Juncture Wealth Strategies investment in Catalyst Pharmaceutical Partners

Tip: Access up to 7 years of quarterly data

All positions including Catalyst Pharmaceutical Partners held by Juncture Wealth Strategies consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Catalyst Pharmaceutical Partners by Juncture Wealth Strategies

Quarter filed Position value Share count Share price at filing
2024-03-31 $1.5M 95k 15.94
2023-12-31 $184k 11k 16.81
2023-09-30 $130k 11k 11.69
2023-06-30 $531k 40k 13.44
2023-03-31 $670k 40k 16.58

More positions owned by Juncture Wealth Strategies

Vanguard Index Fds Large Cap Etf (VV)
Dimensional Etf Trust Us Mktwide Value (DFUV)
Schwab Strategic Tr Us Brd Mkt Etf (SCHB)
Spdr Ser Tr Prtflo S&p500 Vl (SPYV)
Dimensional Etf Trust Us Targeted Vlu (DFAT)
Schwab Strategic Tr Us Dividend Eq (SCHD)
Ishares Tr Core Us Aggbd Et (AGG)
Global X Fds S&p 500 Covered (XYLD)
Vanguard Scottsdale Fds Int-term Corp (VCIT)
Vanguard Scottsdale Fds Shrt Trm Corp Bd (VCSH)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Global X Fds Global X Uranium (URA)
Schwab Strategic Tr Us Sml Cap Etf (SCHA)
Schwab Strategic Tr Us Mid-cap Etf (SCHM)
Ishares Tr Ishs 1-5yr Invs (IGSB)

View all positions for Juncture Wealth Strategies

Top funds holding Catalyst Pharmaceutical Partners

Deerfield Management Company
Vanguard Group
Dimensional Fund Advisors
Royce & Associates
Robeco Investment Management
Jacobs Levy Equity Management
Opaleye Management
LSV Asset Management
T. Rowe Price Associates
Henderson Group
Goldman Sachs Group
Charles Schwab Investment Management
Jupiter Asset Management
Bank of New York Mellon
Bank of America Corporation

View all funds holding Catalyst Pharmaceutical Partners